Gilead Sciences Inc
1GILD
Company Profile
Business description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Contact
333 Lakeside Drive
Foster CityCA94404
USAT: +1 650 574-3000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
17,600
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,424.80 | 59.10 | 0.71% |
| CAC 40 | 7,593.87 | 38.00 | 0.50% |
| DAX 40 | 22,496.98 | 71.15 | 0.32% |
| Dow JONES (US) | 40,752.96 | 83.60 | 0.21% |
| FTSE 100 | 8,496.80 | 1.95 | 0.02% |
| HKSE | 22,411.22 | 291.81 | 1.32% |
| NASDAQ | 17,710.74 | 264.40 | 1.52% |
| Nikkei 225 | 36,705.53 | 253.23 | 0.69% |
| NZX 50 Index | 12,317.68 | 169.08 | 1.39% |
| S&P 500 | 5,604.14 | 35.08 | 0.63% |
| S&P/ASX 200 | 8,204.10 | 58.50 | 0.72% |
| SSE Composite Index | 3,279.03 | 7.62 | -0.23% |